Why PT-141 and nasal spray go together
PT-141 is the development code for bremelanotide, a cyclic peptide that acts at melanocortin receptors. When it was first taken into clinical development, in the 2000s, the formulation being tested was an intranasal one. That programme was stopped, and development continued with an injectable form.
Bremelanotide was approved as a prescription medicine in the United States in 2019, as an injection. The nasal spray never reached the market anywhere, which means every PT-141 nasal spray on sale is an unlicensed product made by its seller.
The formats on sale
Why we do not sell a nasal spray
A nasal spray has one purpose, and it is not a laboratory one. UK medicines law treats a product presented for human use as a medicine, and a medicine needs a licence. A research supplier that sells a compound in a spray bottle has stopped supplying a research material.
There is a quality point too. A spray adds a bottle, a pump and usually a preservative to the compound, and sellers rarely publish a certificate for the finished product. Are peptides legal in the UK? explains how presentation decides a product's status.
PT-141, PT 141 and bremelanotide
The three are one compound. PT-141 was the code used during development and bremelanotide is the name the molecule was given later. A label may carry either or both. What is PT-141? covers the structure and what it is used to study.
What to check on a vial
- The mass in the vial, in milligrams, and for a pre-mixed vial the volume it is dissolved in.
- A certificate of analysis carrying the batch number printed on the vial.
- HPLC purity and a mass spectrometry result confirming identity.
- Cold storage from the supplier to your door.
What we sell
Our bremelanotide (PT-141) 20mg vial is supplied pre-mixed in 3ml, at 6.67mg per ml, with its batch certificate. Refrigerate at 2–8°C and do not freeze. We do not sell it as a nasal spray or in any other form.